Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent vs Continuous Imatinib in TKI-Refractory GIST
NCT02712112Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Mar 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Asan Medical Center. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02712112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02712112.